"The U.S. Food and Drug Administration today expanded the approved use of Opdivo (nivolumab) to treat patients with advanced (metastatic) squamous non-small cell lung cancer (NSCLC) with progression on or after platinum-based chemotherapy.
Patients should be warned to avoid exposure of skin and eyes to direct sunlight or bright indoor light for at least 30 days following injection with PHOTOFRIN (porfimer sodium) .
Patients should be informed that photosensitivity might last for more than 90 days if patients suffer from liver impairment.
Patients should be instructed to wear protective clothing and dark sunglasses when outdoors, which have an average white light transmittance of < 4%.
Patients should be encouraged to expose their skin to ambient indoor light to facilitate elimination of PHOTOFRIN (porfimer sodium) from their skin.
Common Adverse Reactions
Patients should be informed that treatment with photodynamic therapy might lead to adverse reactions which include ocular sensitivity, chest pain, respiratory distress or esophageal strictures. In such cases, patients should call their physicians.
Last reviewed on RxList: 5/19/2011
This monograph has been modified to include the generic and brand name in many instances.
Additional Photofrin Information
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Get the latest treatment options.